GlassScriptPhysician profile
Shankar Thiruppathi
NPI 1508979832
$8,996.42
in general payments reported to CMS, 2019-2025
44 companies · $1,770 in 2025
The $1,770 reported for 2025 was more than what 76% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,001 · 2020: $521 · 2021: $1,305 · 2022: $1,222 · 2023: $1,554 · 2024: $1,622 · 2025: $1,770.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,933 · Education: $13.44.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,932.58 |
| Education | $13.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,703.94 | 2019-2025 | Skyrizi, Rinvoq, Linzess |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,336.28 | 2019-2025 | Xifaxan, Plenvu, Trulance |
| Janssen Biotech, INC. | $402.03 | 2019-2025 | Tremfya, Stelara, Simponi Aria |
| Novo Nordisk INC | $298.56 | 2021-2025 | Wegovy |
| Gilead Sciences, INC. | $297.69 | 2019-2025 | |
| Ardelyx, INC. | $271.53 | 2023-2025 | Ibsrela |
| Merck Sharp & Dohme LLC | $268.70 | 2019-2024 | Dificid, Zinplava |
| Ironwood Pharmaceuticals, INC | $261.87 | 2019-2024 | Linzess |
| Intercept Pharmaceuticals, INC. | $254.16 | 2019-2025 | Ocaliva |
| Takeda Pharmaceuticals U.S.A., INC. | $224.28 | 2019-2025 | Gattex, Entyvio |
| Celgene Corporation | $187.76 | 2022-2024 | Zeposia |
| Genzyme Corporation | $187.30 | 2022-2025 | |
| Braintree Laboratories, INC. | $161.44 | 2019-2023 | Sutab |
| Ipsen Biopharmaceuticals, INC | $158.37 | 2023-2025 | Iqirvo, Bylvay |
| Pfizer INC. | $156.03 | 2021-2025 |
Show all 43 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $151.36 | 2022-2025 | Dupixent |
| Evoke Pharma, INC. | $142.14 | 2020-2023 | Gimoti |
| Xeris Pharmaceuticals, INC. | $126.73 | 2022 | |
| Akebia Therapeutics INC | $123.66 | 2025 | Vafseo |
| Nestle Healthcare Nutrition INC. | $117.93 | 2021-2023 | |
| Madrigal Pharmaceuticals | $110.24 | 2024-2025 | Rezdiffra, Resmetirom |
| Mannkind Corporation | $98.90 | 2023 | Afrezza |
| Boston Scientific Corporation | $88.77 | 2019-2024 | |
| Amarin Pharma, INC. | $81.47 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $81.15 | 2021 | |
| Redhill Biopharma INC. | $74.13 | 2021-2022 | |
| Daiichi Sankyo INC. | $68.01 | 2022-2023 | Injectafer |
| Phathom Pharmaceuticals, INC. | $64.35 | 2024-2025 | Voquezna |
| Allergan, INC. | $62.47 | 2019 | |
| Qol Medical, LLC | $61.06 | 2022-2024 | Sucraid |
| Medtronic, INC. | $48.23 | 2024 | Interstim |
| Lilly USA, LLC | $40.57 | 2023 | Jardiance |
| Organon LLC | $39.27 | 2023-2025 | Renflexis, Hadlima |
| Romark Laboratories, Lc | $36.15 | 2020 | |
| Aimmune Therapeutics, INC. | $34.46 | 2024-2025 | Zenpep |
| Fresenius Kabi USA, LLC | $34.26 | 2023-2024 | Idacio |
| Pharmacosmos Therapeutics INC. | $31.63 | 2022 | |
| Ferring Pharmaceuticals INC. | $28.00 | 2022-2023 | Clenpiq |
| Celltrion USA INC. | $27.92 | 2024-2025 | Vegzelma, Zymfentra |
| Capsovision, INC. | $14.64 | 2025 | Capsocam Plus |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.35 | 2024 | |
| Intra-Sana Laboratories | $12.91 | 2022 | |
| Ambu INC. | $11.72 | 2020 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shankar Thiruppathi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.